GO:1905453 regulation of myeloid progenitor cell differentiation: Hematopoietic Lineage Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905453 describes any process that modulates the frequency, rate or extent of myeloid progenitor cell differentiation, a central node in hematopoietic lineage commitment.
• Myeloid progenitors are transcriptionally heterogeneous and their differentiation is controlled by continuous regulatory landscapes rather than discrete switches.
• Key regulators include transcription factors such as SPI1, CEBPA, GATA2, IRF8, and HOXB8, which coordinate monocyte, macrophage, neutrophil, and dendritic cell output.
• Dysregulation of myeloid progenitor differentiation fuels immunosuppressive macrophage accumulation in tumors and contributes to clonal hematopoiesis and leukemia.
• Cytokine and receptor signaling, including IL-31/IL-31 receptor and NPM1/DNMT3A-dependent programs, modulates progenitor proliferation and survival.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of regulators within this GO term.
Description
Myeloid progenitor cells are bone marrow-derived precursors that give rise to monocytes, macrophages, neutrophils, dendritic cells, and related lineages. The Gene Ontology term GO:1905453, regulation of myeloid progenitor cell differentiation, captures any process that modulates the frequency, rate or extent of the differentiation of these progenitors. Because myeloid progenitors sit at a branch point between self-renewal and lineage commitment, their regulation is central to immune homeostasis, inflammation, and cancer. Single-cell studies have shown that human hematopoietic differentiation follows a continuous regulatory landscape, with myeloid progenitors displaying transcriptional heterogeneity that precedes overt lineage commitment. This means that regulation of myeloid progenitor cell differentiation is not a single switch but a distributed, multi-factor process involving transcription factors, chromatin state, and cytokine signaling. Understanding this GO term is therefore essential for researchers studying innate immunity, tumor immunology, and hematopoietic malignancy.
regulation of myeloid progenitor cell differentiation At A Glance
| GO ID | GO:1905453 |
|---|---|
| GO term | regulation of myeloid progenitor cell differentiation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the frequency, rate or extent of myeloid progenitor cell differentiation |
| Parent process | regulation of cell differentiation |
| Related cell types | Monocytes, macrophages, neutrophils, dendritic cells |
| Key regulators | SPI1, CEBPA, GATA2, IRF8, HOXB8, IL31RA, NPM1, DNMT3A |
| Disease relevance | Tumor immunosuppression, clonal hematopoiesis, leukemia |
What Is GO:1905453?
GO:1905453 is defined by QuickGO as any process that modulates the frequency, rate or extent of myeloid progenitor cell differentiation. In practical terms, it covers the molecular and cellular events that increase, decrease, accelerate, or delay the transition of a myeloid progenitor into a more differentiated myeloid cell. This includes transcriptional control of lineage-specifying genes, cytokine-dependent survival and proliferation signals, and chromatin remodeling that poises progenitors for commitment.
Why Is regulation of myeloid progenitor cell differentiation Important in Cell Biology?
Regulation of myeloid progenitor cell differentiation determines the balance between protective innate immune cells and pathogenic or immunosuppressive myeloid populations. In tumors, dysregulated myeloid progenitors can fuel the accumulation of immunosuppressive macrophages, directly linking this GO term to cancer progression and immunotherapy resistance. In clonal hematopoiesis, mutations such as NPM1 and DNMT3A alter progenitor differentiation programs and predispose to malignant transformation. Because myeloid progenitors are experimentally tractable and clinically relevant, GO:1905453 is a high-value target for mechanistic studies and therapeutic hypothesis generation.
• Controls the production of monocytes, macrophages, neutrophils, and dendritic cells from bone marrow progenitors.
• Shapes the tumor microenvironment by regulating immunosuppressive macrophage generation.
• Underlies clonal hematopoiesis and progression to myeloid malignancy when dysregulated.
• Integrates cytokine signals such as IL-31/IL-31 receptor that modulate progenitor proliferation and survival.
• Depends on continuous transcriptional and chromatin landscapes that can be mapped by single-cell methods.
• Enables ex vivo production of macrophages or neutrophils for research and therapeutic applications.
• Provides a framework for CRISPR-based causal testing of candidate regulators.
• Connects developmental specification of tissue-resident macrophages to adult myeloid homeostasis.
• Serves as a model for studying how transcription factor dosage and timing affect lineage choice.
• Offers biomarkers and intervention points for inflammatory and neoplastic myeloid disorders.
What Happens During regulation of myeloid progenitor cell differentiation?
Transcriptional priming of myeloid progenitors
In simple terms: Before a progenitor commits to a specific cell type, it already has certain genes turned on or poised.
Myeloid progenitors exhibit transcriptional heterogeneity that precedes lineage commitment, with continuous regulatory landscapes rather than discrete states. Transcription factors such as SPI1, CEBPA, and GATA2 establish and maintain progenitor identity while keeping alternative lineage programs accessible. This priming phase determines how progenitors respond to subsequent differentiation cues.
Cytokine and receptor signaling
In simple terms: External signals tell the progenitor whether to survive, divide, or differentiate.
Cytokines and their receptors regulate myeloid progenitor proliferation and survival, thereby influencing differentiation output. IL-31 and its receptor modulate myeloid progenitor proliferation and survival, illustrating how cytokine signaling directly impinges on this GO term. Such signals are integrated with transcription factor networks to set the frequency and rate of differentiation.
Lineage commitment and differentiation
In simple terms: The progenitor makes a decision and begins to become a specific myeloid cell type.
Lineage commitment in myeloid progenitors involves coordinated changes in transcription factor activity and chromatin accessibility. HOXB8-dependent conditional systems can drive quantitative production of macrophages or neutrophils ex vivo, demonstrating that specific regulators can direct lineage output. Specification of tissue-resident macrophages during organogenesis further shows that myeloid differentiation programs are developmentally programmed.
Chromatin and epigenetic control
In simple terms: The way DNA is packaged helps decide which differentiation genes can be turned on.
Integrated single-cell analysis has mapped the continuous regulatory landscape of human hematopoietic differentiation, revealing that chromatin state changes accompany myeloid progenitor differentiation. Epigenetic regulators such as DNMT3A influence the differentiation potential of hematopoietic progenitors, and their mutation alters the trajectory toward malignancy. Thus, regulation of myeloid progenitor cell differentiation is tightly coupled to epigenetic state.
Dysregulation in disease states
In simple terms: When this regulation goes wrong, it can lead to cancer or immune dysfunction.
Myeloid progenitor dysregulation can fuel immunosuppressive macrophage accumulation in tumors, directly linking GO:1905453 to cancer immunology. Sequentially inducible mouse models show that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis, implicating altered progenitor differentiation in leukemia. These findings position regulation of myeloid progenitor cell differentiation as a key node in both solid tumor and hematologic disease.
Key Genes Involved in GO:1905453 regulation of myeloid progenitor cell differentiation
The following genes and proteins have been experimentally implicated in the regulation of myeloid progenitor cell differentiation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPI1 | Master myeloid transcription factor | Controls monocyte/macrophage lineage commitment |
| CEBPA | Myeloid lineage transcription factor | Regulates granulocyte-monocyte progenitor differentiation |
| GATA2 | Hematopoietic stem/progenitor transcription factor | Maintains progenitor pool and differentiation potential |
| IRF8 | Dendritic cell and monocyte regulator | Controls lineage choice in myeloid progenitors |
| HOXB8 | Conditional immortalization and differentiation regulator | Enables ex vivo macrophage/neutrophil production |
| IL31RA | IL-31 receptor subunit | Modulates myeloid progenitor proliferation/survival |
| NPM1 | Nucleolar protein with leukemic mutations | Mutation transforms Dnmt3a-mutant clonal hematopoiesis |
| DNMT3A | DNA methyltransferase | Epigenetic regulator of progenitor differentiation |
| CSF1R | Macrophage colony-stimulating factor receptor | Drives monocyte/macrophage differentiation |
| CSF2RB | GM-CSF receptor beta chain | Supports granulocyte/macrophage progenitor expansion |
| MPO | Myeloperoxidase | Marker of granulocyte differentiation |
| LYZ | Lysozyme | Marker of monocyte/macrophage differentiation |
| ITGAM | Integrin alpha-M | Myeloid differentiation surface marker |
| FCGR3 | Fc gamma receptor III | Mature myeloid cell marker |
| KIT | Stem cell factor receptor | Maintains progenitor proliferation |
| PTPRC | CD45 pan-leukocyte marker | Used to identify hematopoietic progenitors |
| RUNX1 | Hematopoietic transcription factor | Required for emergence of myeloid lineages |
How Is regulation of myeloid progenitor cell differentiation Regulated?
Regulation of myeloid progenitor cell differentiation is controlled by an integrated network of transcription factors, cytokine signaling, and epigenetic modifiers. Cytokines such as IL-31 act through their receptors to modulate progenitor proliferation and survival, thereby influencing differentiation frequency and rate. Epigenetic regulators including DNMT3A and nucleolar proteins such as NPM1 further shape differentiation potential, and their mutation can redirect progenitor fate toward malignancy. Single-cell chromatin accessibility mapping has revealed that these regulatory inputs operate across a continuous landscape rather than discrete checkpoints.
regulation of myeloid progenitor cell differentiation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPM1 | Clonal hematopoiesis and leukemia transformation | Sequentially inducible Npm1 mutation in Dnmt3a-mutant mice |
| DNMT3A | Clonal hematopoiesis and myeloid malignancy | Dnmt3a knockout or point-mutation models |
| SPI1 | Myeloid lineage commitment defects | CRISPR knockout in hematopoietic progenitors |
| IL31RA | Myeloid progenitor proliferation/survival | IL-31 receptor knockout or overexpression |
| HOXB8 | Ex vivo myeloid differentiation | Conditional Hoxb8 immortalization system |
Tumor immunosuppression
Myeloid progenitor dysregulation fuels the accumulation of immunosuppressive macrophages in tumors, linking GO:1905453 to cancer progression and immune evasion. Targeting the regulators of myeloid progenitor differentiation may therefore improve antitumor immunity.
Clonal hematopoiesis and leukemia
Sequentially inducible mouse models demonstrate that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis, directly implicating altered myeloid progenitor differentiation in leukemogenesis. DNMT3A and NPM1 mutations are therefore key experimental handles for studying this GO term in disease.
Inflammatory and myeloid disorders
Because myeloid progenitors give rise to monocytes, macrophages, neutrophils, and dendritic cells, dysregulation of their differentiation can contribute to inflammatory pathology and immune dysfunction. Cytokine signals such as IL-31 further modulate progenitor behavior, suggesting additional disease-relevant axes.
From regulation of myeloid progenitor cell differentiation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for myeloid progenitor differentiation? | CRISPR knockout in primary progenitors or cell lines |
| Does a specific point mutation alter differentiation rate? | CRISPR point-mutation knock-in |
| Does a disease-associated variant affect lineage choice? | Knock-in of the variant allele |
| Where and when is a regulator expressed during differentiation? | Tagged knock-in reporter |
| Does overexpression of a factor expand or block a lineage? | Overexpression cell model |
| Can a cytokine receptor modulate progenitor output? | Receptor knockout or overexpression |
How to Study the regulation of myeloid progenitor cell differentiation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| scRNA-seq | Transcriptional heterogeneity of progenitors | Map differentiation trajectories |
| scATAC-seq | Chromatin accessibility landscape | Identify regulatory elements |
| CRISPR knockout screen | Gene requirement for differentiation | Discover regulators |
| CRISPR point-mutation knock-in | Effect of specific variants | Model disease mutations |
| Ex vivo Hoxb8 differentiation | Macrophage/neutrophil output | Quantitative differentiation assays |
| Cytokine stimulation assays | Proliferation/survival response | Test IL-31/IL-31R signaling |
| Inducible mouse models | In vivo transformation potential | Study clonal hematopoiesis |
| Flow cytometry | Surface marker expression | Assess lineage commitment |
Single-cell transcriptomics and chromatin accessibility
Integrated single-cell analysis has mapped the continuous regulatory landscape of human hematopoietic differentiation, enabling researchers to resolve myeloid progenitor heterogeneity and commitment trajectories. These methods are essential for defining the regulatory states that underlie GO:1905453.
Functional CRISPR screens
CRISPR knockout and point-mutation screens can test which genes causally regulate myeloid progenitor differentiation. Such screens are particularly powerful when combined with single-cell readouts to link genotype to differentiation phenotype.
Ex vivo differentiation assays
Conditional Hoxb8 systems allow quantitative production of macrophages or neutrophils ex vivo, providing a controlled platform to study regulators of myeloid progenitor differentiation. These assays can be coupled with cytokine treatments such as IL-31 to probe signaling inputs.
Mouse models of clonal hematopoiesis
Sequentially inducible mouse models reveal how mutations such as Npm1 and Dnmt3a cooperate to transform myeloid progenitors, offering in vivo validation of regulatory mechanisms. These models are critical for linking GO:1905453 to leukemia pathogenesis.
How CRISPR Can Be Used to Study GO:1905453 regulation of myeloid progenitor cell differentiation
Knockout
CRISPR knockout of candidate regulators in hematopoietic progenitors can determine whether a gene is required for myeloid progenitor differentiation. This approach is widely used to validate hits from single-cell and screen-based studies.
Point Mutation
CRISPR point-mutation knock-in enables precise modeling of disease-associated variants, such as those in NPM1 or DNMT3A, to test their effect on differentiation rate and lineage choice. This is essential for distinguishing driver from passenger mutations.
Knock-in
Tagged knock-in reporters can track the expression and localization of regulators during myeloid progenitor differentiation. Knock-in of fluorescent or epitope tags facilitates live-cell imaging and proteomic analysis.
Overexpression
Overexpression models can test whether a factor is sufficient to expand, block, or redirect myeloid progenitor differentiation. For example, conditional Hoxb8 overexpression supports ex vivo macrophage or neutrophil production.
How EDITGENE Supports regulation of myeloid progenitor cell differentiation Research
Researchers studying regulation of myeloid progenitor cell differentiation-related genes often need to determine whether a candidate gene is causally involved in lineage commitment, proliferation, or disease transformation. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such studies.
Contact EDITGENE today to design your custom CRISPR model for regulation of myeloid progenitor cell differentiation research.
Frequently Asked Questions About regulation of myeloid progenitor cell differentiation
What is GO:1905453?
GO:1905453 is the Gene Ontology term for regulation of myeloid progenitor cell differentiation, defined as any process that modulates the frequency, rate or extent of myeloid progenitor cell differentiation.
What genes are involved in regulation of myeloid progenitor cell differentiation?
Key genes include SPI1, CEBPA, GATA2, IRF8, HOXB8, IL31RA, NPM1, and DNMT3A, among others.
Why is regulation of myeloid progenitor cell differentiation important?
It controls the production of innate immune cells and, when dysregulated, contributes to tumor immunosuppression and leukemia.
How is myeloid progenitor differentiation regulated?
It is regulated by transcription factors, cytokine signaling, and epigenetic modifiers that together set the frequency and rate of differentiation.
What diseases are linked to myeloid progenitor differentiation?
Diseases include clonal hematopoiesis, leukemia, and tumor-associated immunosuppression.
What methods study myeloid progenitor differentiation?
Single-cell RNA-seq, scATAC-seq, CRISPR screens, ex vivo differentiation assays, and inducible mouse models are commonly used.
Can CRISPR be used to study myeloid progenitor differentiation?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate regulators.
What is the role of IL-31 in myeloid progenitors?
IL-31 and its receptor regulate myeloid progenitor proliferation and survival, thereby influencing differentiation.
How do NPM1 and DNMT3A mutations affect myeloid differentiation?
Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis, linking altered differentiation to leukemia.
What cell types arise from myeloid progenitors?
Myeloid progenitors give rise to monocytes, macrophages, neutrophils, and dendritic cells.
Conclusion
GO:1905453, regulation of myeloid progenitor cell differentiation, is a central biological process that integrates transcriptional, signaling, and epigenetic inputs to control innate immune cell production. Its dysregulation is directly implicated in tumor immunosuppression and clonal hematopoiesis, making it a high-priority area for mechanistic and translational research. CRISPR-based models and single-cell technologies now provide the tools needed to dissect this process with unprecedented resolution.
References
- 1. Hegde S et al.. 2025. Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumours.. Nature 646(8087):1214-1222 PMID: 40931076
- 2. Buenrostro JD et al.. 2018. Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation.. Cell 173(6):1535-1548.e16 PMID: 29706549
- 3. Geissmann F et al.. 2010. Development of monocytes, macrophages, and dendritic cells.. Science 327(5966):656-61 PMID: 20133564
- 4. Mass E et al.. 2016. Specification of tissue-resident macrophages during organogenesis.. Science 353(6304) PMID: 27492475
- 5. Paul F et al.. 2015. Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors.. Cell 163(7):1663-77 PMID: 26627738
- 6. Wang GG et al.. 2006. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8.. Nat Methods 3(4):287-93 PMID: 16554834
- 7. Broxmeyer HE et al.. 2007. Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31.. Exp Hematol 35(4 Suppl 1):78-86 PMID: 17379091
- 8. Loberg MA et al.. 2019. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.. Leukemia 33(7):1635-1649 PMID: 30692594
